AJP - GI Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Gastrointest Liver Physiol 290: G404-G416, 2006. First published October 6, 2005; doi:10.1152/ajpgi.00344.2005
0193-1857/06 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/2/G404    most recent
00344.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takaoka, M.
Right arrow Articles by Nakagawa, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takaoka, M.
Right arrow Articles by Nakagawa, H.

HORMONES AND SIGNALING

EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I

Munenori Takaoka,1 Caitlin E. Smith,1 Michael K. Mashiba,1 Takaomi Okawa,1 Claudia D. Andl,1 Wafik S. El-Deiry,2,3,4 and Hiroshi Nakagawa1

1Gastroenterology Division, Departments of 2Medicine, 3Genetics, and 4Pharmacology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania

Submitted 26 July 2005 ; accepted in final form 5 October 2005

IGF and EGF regulate various physiological and pathological processes. IGF binding protein (IGFBP)-3 regulates cell proliferation in IGF-dependent and -independent fashions. Recently, we identified IGFBP-3 as a novel EGF receptor (EGFR) downstream target molecule in primary and immortalized human esophageal epithelial cells, suggesting an interplay between the EGF and IGF signaling pathways. However, the regulatory mechanisms for IGFBP-3 expression and its functional role in esophageal cell proliferation remain to be elucidated. Herein, we report that IGFBP-3 mRNA and protein were induced upon growth factor deprivation in primary and immortalized human esophageal cells through mechanisms requiring p53-independent de novo mRNA transcription and protein synthesis. This occurred in the face of the activated phosphatidylinositol 3-OH-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway. Secreted IGFBP-3 neutralized IGFs and prevented IGF-I receptor (IGF-IR) activation. In contrast, EGF suppressed IGFBP-3 mRNA and protein expression through activation of MAPK in an EGFR-tyrosine kinase-dependent manner to restore the cellular response to IGF-I. When stably overexpressed, wild-type IGFBP-3 but not I56G/L80G/L81G (GGG) mutant IGFBP-3, which has a reduced affinity to IGFs, prevented IGF-I from activating IGF-IR and Akt as well as stimulating cell proliferation. However, unlike other cell types where IGFBP-3 exerts antiproliferative effects, neither wild-type nor GGG mutant IGFBP-3 alone affected cell proliferation or EGFR activity. These results indicate that IGF signaling is subject to negative regulation through IGFBP-3 and positive regulation by EGF, the latter of which suppresses IGFBP-3. This provides a platform for understanding the novel cross talk between EGF- and IGF-mediated pathways.

insulin-like growth factor binding protein-3; epidermal growth factor receptor; mammalian target of rapamycin; esophageal epithelial cells



Address for reprint requests and other correspondence: H. Nakagawa, 638B CRB, Gastroenterology Div., Univ. of Pennsylvania, 415 Curie Blvd., Philadelphia, PA 19104 (e-mail: nakagawh{at}mail.med.upenn.edu)




This article has been cited by other articles:


Home page
CJASNHome page
C. L. Edelstein
Mammalian Target of Rapamycin and Caspase Inhibitors in Polycystic Kidney Disease
Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1219 - 1226.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Yamasaki, M. J. Johansen, D. Zhang, S. Krishnamurthy, E. Felix, C. Bartholomeusz, R. J. Aguilar, K. Kurisu, G. B. Mills, G. N. Hortobagyi, et al.
Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt
Cancer Res., June 15, 2007; 67(12): 5779 - 5788.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.